CA2396351A1 - Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques - Google Patents

Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques Download PDF

Info

Publication number
CA2396351A1
CA2396351A1 CA002396351A CA2396351A CA2396351A1 CA 2396351 A1 CA2396351 A1 CA 2396351A1 CA 002396351 A CA002396351 A CA 002396351A CA 2396351 A CA2396351 A CA 2396351A CA 2396351 A1 CA2396351 A1 CA 2396351A1
Authority
CA
Canada
Prior art keywords
antipsychotic
antipsychotic agent
dioxino
indol
benzylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002396351A
Other languages
English (en)
Other versions
CA2396351C (fr
Inventor
Karen Lovell Marquis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth
Karen Lovell Marquis
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth, Karen Lovell Marquis, American Home Products Corporation filed Critical Wyeth
Publication of CA2396351A1 publication Critical patent/CA2396351A1/fr
Application granted granted Critical
Publication of CA2396351C publication Critical patent/CA2396351C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des combinaisons thérapeutiques, utiles dans le traitement ou la prévention de troubles psychotiques; elle concerne également des compositions pharmaceutiques contenant ces combinaisons, ainsi que l'utilisation de celles-ci dans le traitement ou la prophylaxie de troubles psychotiques.
CA002396351A 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques Expired - Lifetime CA2396351C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10
US09/458,607 1999-12-10
PCT/US2000/033060 WO2001041750A2 (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques

Publications (2)

Publication Number Publication Date
CA2396351A1 true CA2396351A1 (fr) 2001-06-14
CA2396351C CA2396351C (fr) 2009-11-10

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396351A Expired - Lifetime CA2396351C (fr) 1999-12-10 2000-12-07 Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques

Country Status (20)

Country Link
EP (1) EP1235570A2 (fr)
JP (1) JP5557409B2 (fr)
KR (1) KR100772854B1 (fr)
CN (1) CN1230164C (fr)
AR (1) AR026756A1 (fr)
AU (1) AU784211B2 (fr)
BR (1) BR0016168A (fr)
CA (1) CA2396351C (fr)
CZ (1) CZ20021880A3 (fr)
EA (1) EA005002B1 (fr)
HK (1) HK1045942A1 (fr)
HU (1) HUP0203309A3 (fr)
IL (2) IL149669A0 (fr)
MX (1) MXPA02005649A (fr)
NO (1) NO20022739D0 (fr)
NZ (1) NZ519381A (fr)
PL (1) PL355292A1 (fr)
TW (1) TWI222864B (fr)
WO (1) WO2001041750A2 (fr)
ZA (1) ZA200205484B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG147450A1 (en) 2003-10-29 2008-11-28 Wyeth Corp Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
CA2597616A1 (fr) 2005-02-17 2006-08-24 Wyeth Derive d'indole, benzothiophene, benzofurane et indene a fusion cycloalkyle
SG188144A1 (en) * 2008-02-13 2013-03-28 Targacept Inc Alpha 7 nicotinic agonists and antipsychotics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
TWI222864B (en) 2004-11-01
BR0016168A (pt) 2002-08-20
AR026756A1 (es) 2003-02-26
HUP0203309A2 (hu) 2003-01-28
CA2396351C (fr) 2009-11-10
NZ519381A (en) 2004-04-30
CZ20021880A3 (cs) 2002-08-14
AU1949001A (en) 2001-06-18
WO2001041750A3 (fr) 2002-02-14
EA200200656A1 (ru) 2002-12-26
EA005002B1 (ru) 2004-10-28
CN1230164C (zh) 2005-12-07
CN1409633A (zh) 2003-04-09
JP5557409B2 (ja) 2014-07-23
KR20030016207A (ko) 2003-02-26
AU784211B2 (en) 2006-02-23
PL355292A1 (en) 2004-04-05
ZA200205484B (en) 2003-12-31
NO20022739L (no) 2002-06-07
HK1045942A1 (zh) 2002-12-20
KR100772854B1 (ko) 2007-11-02
MXPA02005649A (es) 2004-09-10
WO2001041750A2 (fr) 2001-06-14
JP2003516350A (ja) 2003-05-13
HUP0203309A3 (en) 2004-12-28
NO20022739D0 (no) 2002-06-07
IL149669A0 (en) 2002-11-10
EP1235570A2 (fr) 2002-09-04
IL149669A (en) 2006-06-11

Similar Documents

Publication Publication Date Title
AU762481C (en) Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
EP1243267A3 (fr) Composition pharmaceutique contenant de l'amoxicilline et du clavulanate
RU2000104121A (ru) Терапевтические и диетические композиции, содержащие необходимые жирные кислоты и биологически активные дисульфиды
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
TW366286B (en) Flavour-masked pharmaceutical compositions
IL119627A0 (en) Controlled-release pharmaceutical preparations
WO2003039436A3 (fr) Compositions pharmaceutiques contenant de l'oxybutine
AU1099288A (en) Drug delivery system and method of making the same
WO2001095899A8 (fr) Compositions pharmaceutiques renfermant des derives de cannabidiol
MY130098A (en) Local drug delivery film for periodontal treatment
DE69521688T2 (de) Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung
KR20010005677A (ko) 정신병성 질환의 치료 또는 예방을 위한 미르타자핀 및 항정신병제의 신규한 치료 조합물
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
US6566389B1 (en) Therapeutic uses of melatonin
KR101000624B1 (ko) 멜라토닌을 포함하는 약제학적 제제
CA2396351A1 (fr) Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques
KR100420673B1 (ko) 지연된구토반응을치료하기위한비강투여제
CA2474430A1 (fr) Polytherapie combinant un agent thrombolytique et du levosimendane pour le traitement de l'infractus aigu du myocarde
ATE212550T1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
EP1197227A4 (fr) Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede
JP7081002B2 (ja) 液状口腔咽喉薬
RU2003106417A (ru) Применение комбинации витаминов для лечения первичных головных болей
CA2336711A1 (fr) Plaquette alveolaire contenant un systeme therapeutique transdermique et une forme galenique individuelle
CZ5821U1 (cs) Farmaceutický přípravek pro léčení hernofilie a použití hormonu mestranolu

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20201207